Prodrug activation, by exogenously administered enzymes, for cancertherapy is an approach to achieve better selectivity and less systemic toxicity than conventional chemotherapy. However, the short half‐lives of the activating enzymes in the bloodstream has limited its success. Demonstrated here is that a tyrosinase‐MOF nanoreactoractivates the prodrug paracetamol in cancer cells in a long‐lasting